Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Website: novavax.com



Growth: Bad revenue growth rate -2.9%, there is slowdown compared to average historical growth rates 17.8%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of -38.7%

Profitability: LTM EBITDA margin is negative, -17.0%. On average the margin is improving steadily. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 20% of quarters (showing a gain of -$3.44 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -13.4% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 126.9% higher than minimum and 59.3% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 1.3x by EV / Sales multiple , the company can be 51.3% overvalued

Key Financials (Download financials)

Ticker: NVAX
Share price, USD:  (-2.6%)8.53
year average price 9.09  


year start price 6.97 2025-11-16

min close price 6.22 2025-11-20

max close price 13.09 2026-10-05

current price 8.53 2026-11-15
Common stocks: 164 924 000

Dividend Yield:  0.0%
EV / Sales: 2.6x
Margin (EBITDA LTM / Revenue): -17.0%
Fundamental value created in LTM:
Market Cap ($m): 1 407
Net Debt ($m): -330
EV (Enterprise Value): 1 077
Price to Book: -9.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-01-22zacks.com

Novavax (NVAX) Stock Dips While Market Gains: Key Facts

2026-01-21zacks.com

Novavax Grants License for Use of Matrix-M Adjuvant to Pfizer

2026-01-14seekingalpha.com

Novavax, Inc. (NVAX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2025-11-19seekingalpha.com

Novavax, Inc. (NVAX) Presents at Jefferies London Healthcare Conference 2025 Transcript

2025-11-06zacks.com

Novavax (NVAX) Reports Q3 Loss, Beats Revenue Estimates

2025-10-06zacks.com

Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade

2025-09-30zacks.com

Novavax (NVAX) Exceeds Market Returns: Some Facts to Consider

2025-09-26zacks.com

Here's Why Novavax (NVAX) is a Strong Momentum Stock

2025-09-04seekingalpha.com

Novavax, Inc. (NVAX) Presents At Cantor Global Healthcare Conference 2025 Transcript

2025-08-28zacks.com

Why Novavax (NVAX) is a Top Momentum Stock for the Long-Term
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol NVAX NVAX NVAX NVAX NVAX NVAX NVAX NVAX NVAX NVAX NVAX NVAX NVAX NVAX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-06 2025-08-06 2024-11-12 2024-08-08 2024-05-10 2023-11-09 2023-08-08 2023-05-09 2022-11-09
acceptedDate 2025-11-06 07:47:47 2025-08-06 07:47:13 2025-02-27 07:41:08 2024-11-12 16:08:10 2024-08-08 07:37:07 2024-05-10 08:05:26 2024-02-28 07:30:55 2023-11-09 07:32:56 2023-08-08 06:30:51 2023-05-09 08:00:45 2023-02-28 16:27:00 2022-11-09 09:01:49 2022-02-28 21:13:09 2021-03-01 16:42:41
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 70M 239M 682M 85M 415M 94M 556M 22M 424M 81M 1 599M 735M 198M 22M
costOfRevenue 21M 14M 203M 61M 36M 49M 344M 99M 56M 34M 903M 435M 0 0
grossProfit 49M 225M 479M 24M 379M 45M 213M -77M 369M 47M 696M 300M 198M 22M
grossProfitRatio 0.695 0.941 0.283 0.913 0.48 -3.484 0.869 0.579 0.408
researchAndDevelopmentExpenses 98M 78M 391M 87M 107M 93M 738M 106M 219M 247M 1 235M 304M 2 535M 747M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 489M 0 298M 145M
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 32M 41M 337M 71M 101M 82M 469M 107M 94M 113M 489M 123M 298M 145M
otherExpenses 97M 1M 0 0 0 -9M -427M -3M 6M -87M -383M 0 -949M -453M
operatingExpenses 227M 119M 728M 158M 208M 184M 779M 49M 313M 272M 1 341M 427M 1 884M 439M
costAndExpenses 248M 134M 931M 219M 253M 233M 1 123M 148M 369M 306M 2 244M 862M 1 884M 439M
interestIncome 0 0 0 0 0 0 0 3M 3M 0 0 0 0 0
interestExpense 5M 6M 20M 4M 4M 4M 14M 3M 3M 4M 20M 4M 21M 15M
depreciationAndAmortization 7M 8M 48M 13M 11M 12M 41M 11M 10M 33M 29M -26M 13M 5M
ebitda -191M 121M -108M -105M 180M -127M -487M -117M 71M -279M -605M -154M -1 681M -398M
ebitdaratio -2.711 0.504 -1.247 0.433 -1.349 -5.316 0.167 -3.451 -0.209
operatingIncome -178M 106M -249M -134M 161M -139M -567M -126M 55M -313M -645M -127M -1 687M -417M
operatingIncomeRatio -2.527 0.442 -1.586 0.387 -1.478 -5.694 0.131 -3.864 -0.173
totalOtherIncomeExpensesNet -25M 2M 72M 12M 4M -7M 23M -3M 6M 20M -9M -39M -28M -2M
incomeBeforeTax -203M 107M -177M -122M 165M -145M -543M -131M 58M -293M -654M -166M -1 715M -418M
incomeBeforeTaxRatio -2.882 0.449 -1.448 0.396 -1.548 -5.959 0.136 -3.616 -0.226
incomeTaxExpense -657 000 946 000 11M -1M 2M 2M 2M -697 000 -143 000 1M 4M 2M 29M 0
netIncome -202M 107M -187M -121M 162M -148M -545M -131M 58M -294M -658M -169M -1 744M -418M
netIncomeRatio -2.873 0.445 -1.435 0.391 -1.572 -5.927 0.137 -3.631 -0.23
eps -1.25 0.66 -1.23 -0.76 1.11 -1.05 -5.41 -1.26 0.65 -3.41 -8.42 -2.15 -23.44 -7.43
epsdiluted -1.25 0.6 -0.76 0.99 -1.05 -1.26 0.58 -3.41 -2.15
weightedAverageShsOut 162M 162M 152M 160M 148M 140M 101M 103M 104M 86M 78M 78M 74M 58M
weightedAverageShsOutDil 162M 177M 152M 160M 166M 140M 101M 103M 104M 86M 78M 78M 74M 58M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-28 2023-02-28 2022-03-01 2021-03-01
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -20M -14M -20M -21M -15M
ebit -157M -529M -634M -1 693M -403M
nonOperatingIncomeExcludingInterest -92M -38M -11M 7M -14M
netIncomeFromContinuingOperations -187M -545M -658M -1 744M -418M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -187M -545M -658M -1 744M -418M
epsDiluted -1.23 -5.41 -8.42 -23.44 -7.43

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol NVAX NVAX NVAX NVAX NVAX NVAX NVAX NVAX NVAX NVAX NVAX NVAX NVAX NVAX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-06 2025-08-06 2024-11-12 2024-08-08 2024-05-10 2023-11-09 2023-08-08 2023-05-09 2022-11-09
acceptedDate 2025-11-06 07:47:47 2025-08-06 07:47:13 2025-02-27 07:41:08 2024-11-12 16:08:10 2024-08-08 07:37:07 2024-05-10 08:05:26 2024-02-28 07:30:55 2023-11-09 07:32:56 2023-08-08 06:30:51 2023-05-09 08:00:45 2023-02-28 16:27:00 2022-11-09 09:01:49 2022-02-28 21:13:09 2021-03-01 16:42:41
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 268M 254M 530M 574M 691M 491M 569M 651M 506M 625M 1 337M 1 281M 1 515M 553M
shortTermInvestments 495M 359M 393M 336M 369M 0 0 0 0 0 0 0 0 158M
cashAndShortTermInvestments 763M 612M 923M 910M 1 050M 491M 569M 651M 506M 625M 1 337M 1 281M 1 515M 711M
netReceivables 34M 226M 108M 95M 32M 21M 297M 124M 395M 113M 82M 112M 455M 262M
inventory 14M 10M 9M 9M 9M 16M 42M 70M 23M 34M 37M 82M 0 0
otherCurrentAssets 164M 71M 33M 91M 112M 199M 166M 152M 193M 189M 87M 285M 56M 104M
totalCurrentAssets 975M 920M 1 129M 1 104M 1 203M 727M 1 144M 1 007M 1 128M 971M 1 703M 1 760M 2 155M 1 248M
propertyPlantEquipmentNet 73M 283M 300M 451M 458M 472M 491M 492M 396M 411M 400M 364M 229M 180M
goodwill 113M 113M 107M 127M 123M 123M 127M 124M 128M 130M 126M 118M 131M 135M
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 8M 5M 6M
goodwillAndIntangibleAssets 113M 113M 107M 127M 123M 123M 127M 124M 128M 130M 126M 126M 136M 141M
longTermInvestments 0 0 0 0 5M 5M 0 5M 2M 0 2M 0 2M 0
taxAssets 0 0 0 0 -5M 0 0 -5M -2M 0 -2M 0 -2M 0
otherNonCurrentAssets 19M 21M 24M 31M 29M 26M 35M 35M 33M 31M 28M 17M 57M 13M
totalNonCurrentAssets 205M 417M 431M 609M 615M 626M 654M 650M 557M 572M 555M 507M 422M 334M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 1 180M 1 337M 1 560M 1 712M 1 819M 1 354M 1 797M 1 657M 1 685M 1 543M 2 259M 2 267M 2 577M 1 582M
accountPayables 15M 51M 42M 58M 80M 58M 133M 102M 87M 125M 217M 145M 127M 54M
shortTermDebt 5M 6M 0 10M 19M 6M 0 1M 953 000 1M 325M 407M 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 104M 114M 675M 613M 666M 241M 241M 192M 300M 416M 370M 405M 1 423M 273M
otherCurrentLiabilities 305M 219M 280M 500M 393M 499M 917M 1 173M 1 208M 1 377M 983M 712M 74M 30M
totalCurrentLiabilities 430M 389M 1 154M 1 181M 1 158M 804M 1 635M 1 469M 1 596M 1 919M 2 460M 1 668M 2 390M 580M
longTermDebt 246M 223M 170M 224M 224M 168M 168M 221M 198M 198M 166M 31M 323M 322M
deferredRevenueNonCurrent 0 399M 447M 0 533M 841M 622M 609M 607M 274M 179M 1 035M 173M 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 55M 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 661M 288M 360M 834M 335M 352M 33M 37M 38M 48M 56M 209M 42M 13M
totalNonCurrentLiabilities 907M 910M 1 030M 1 058M 1 093M 1 416M 879M 867M 843M 519M 433M 1 165M 538M 376M
otherLiabilities 0 0 0 0 0 1 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 58M 61M 64M 64M 55M 61M 54M 32M 32M 58M 114M 131M 146M
totalLiabilities 1 337M 1 299M 2 184M 2 239M 2 250M 2 221M 2 514M 2 336M 2 440M 2 438M 2 893M 2 833M 2 928M 955M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 2M 2M 2M 2M 2M 1M 1M 1M 952 000 871 000 868 000 792 000 764 000 714 000
retainedEarnings -4 586M -4 383M -5 008M -4 927M -4 806M -4 969M -4 821M -4 643M -4 512M -4 570M -4 276M -4 094M -3 618M -1 874M
accumulatedOtherComprehensiveIncomeLoss -2M -458 000 -23M 4M -11M -11M 3M -12M -8M -3M -6M -24M -1M 7M
othertotalStockholdersEquity 4 429M 4 420M 4 396M 4 383M 4 111M 3 975M 3 764M 3 677M 3 551M
totalStockholdersEquity -157M 38M -624M -526M -432M -867M -717M -678M -755M -896M -634M -566M -352M 627M
totalEquity -157M 38M -624M -526M -432M -867M -717M -678M -755M -896M -634M -566M -352M 627M
totalLiabilitiesAndStockholdersEquity 1 180M 1 337M 1 712M 1 819M 1 354M 1 657M 1 685M 1 543M 2 267M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 180M 1 337M 1 560M 1 712M 1 819M 1 354M 1 797M 1 657M 1 685M 1 543M 2 259M 2 267M 2 577M 1 582M
totalInvestments 495M 359M 393M 336M 374M 5M 0 5M 2M 0 2M 0 2M 158M
totalDebt 251M 228M 230M 233M 233M 229M 229M 222M 199M 199M 550M 438M 454M 468M
netDebt -17M -25M -300M -340M -447M -262M -339M -429M -307M -426M -787M -842M -1 061M -85M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-28 2023-02-28 2022-03-01 2021-03-01
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 108M 297M 82M 455M 262M
otherReceivables 0 0 0 0 0
prepaids 56M 70M 161M 120M 172M
totalPayables 42M 133M 217M 127M 54M
otherPayables 0 0 0 0 0
accruedExpenses 151M 339M 539M 635M 117M
capitalLeaseObligationsCurrent 7M 5M 27M 131M 106M
capitalLeaseObligationsNonCurrent 54M 56M 31M 0 40M
treasuryStock -96M -92M -91M -85M -42M
additionalPaidInCapital 4 501M 4 192M 3 738M 3 352M 2 535M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol NVAX NVAX NVAX NVAX NVAX NVAX NVAX NVAX NVAX NVAX NVAX NVAX NVAX NVAX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-06 2025-08-06 2024-11-12 2024-08-08 2024-05-10 2023-11-09 2023-08-08 2023-05-09 2022-11-09
acceptedDate 2025-11-06 07:47:47 2025-08-06 07:47:13 2025-02-27 07:41:08 2024-11-12 16:08:10 2024-08-08 07:37:07 2024-05-10 08:05:26 2024-02-28 07:30:55 2023-11-09 07:32:56 2023-08-08 06:30:51 2023-05-09 08:00:45 2023-02-28 16:27:00 2022-11-09 09:01:49 2022-02-28 21:13:09 2021-03-01 16:42:41
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -202M 107M -187M -121M 162M -148M -545M -131M 58M -294M -658M -169M -1 744M -418M
depreciationAndAmortization 7M 8M 48M 13M 11M 12M 41M 11M 10M 9M 29M 8M 13M 5M
deferredIncomeTax 0 0 0 0 0 0 0 18M 29M 0 0 0 0 0
stockBasedCompensation 9M 9M 48M 12M 14M 12M 85M 21M 20M 29M 130M 32M 184M 128M
changeInWorkingCapital 166M -240M 48M -149M 115M 34M -377M 44M -291M -81M -361M -131M 1 734M 12M
accountsReceivables 208M -169M 354M -38M 95M 296M -274M 232M -285M 18M 249M 58M -192M -423M
inventory -4M -4M 13M -1M -3M 17M -74M -63M -10M -9M -478M -23M -600M 0
accountsPayables -27M -63M -386M 23M -94M -272M -379M 94M -213M -230M 913M -89M 600M 163M
otherWorkingCapital -12M -5M 67M -134M 117M -6M 351M -219M 218M 140M -1 046M -78M 1 926M 272M
otherNonCashItems 129M -10M -45M 101M 11M 1M 81M -3M 1M 11M 444M 221M 137M 231M
netCashProvidedByOperatingActivities 108M -127M -87M -145M 314M -84M -714M -40M -172M -326M -416M -39M 323M -43M
investmentsInPropertyPlantAndEquipment -2M -247 000 -15M -750 000 -3M -7M -59M -18M -8M -24M -93M -30M -57M -55M
acquisitionsNet 0 0 193M 0 0 0 0 0 0 0 0 0 57M -166M
purchasesOfInvestments -235M 0 -826M -72M 0 0 0 0 0 0 0 0 -2M -363M
salesMaturitiesOfInvestments 101M 112M 444M 0 0 0 0 0 0 0 0 0 160M 206M
otherInvestingActivites 0 -280 000 104M -370M -372 000 -233 000 0 0 0
netCashUsedForInvestingActivites -137M 111M 32M -373M -7M -18M -8M -24M -30M
debtRepayment 42M -612 000 -512 000 -366 000 -360 000 -2M -453 000 -351M -30M
commonStockIssued 0 0 -2M 256M 6M 195M 62M 543 000 0
commonStockRepurchased 820 000 -428 000 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 0 415 000 2M -976 000 4M -198 000 -4M -983 000
netCashUsedProvidedByFinancingActivities 42M -1M -97 000 258M 6M 197M 61M -354M -31M
effectOfForexChangesOnCash 629 000 8M -8M 6M -156 000 -3M 3M 9M -620 000 -8M 5M 5M -5M 2M
netChangeInCash 14M -9M -39M -102M 200M -88M -765M 148M -119M -712M -179M -94M 880M 567M
cashAtEndOfPeriod 279M 269M 545M 589M 691M 491M 584M 666M 518M 637M 1 349M 1 293M 1 528M 649M
cashAtBeginningOfPeriod 264M 278M 584M 691M 491M 579M 1 349M 518M 637M 1 349M 1 528M 1 388M 649M 82M
operatingCashFlow 108M -127M -87M -145M 314M -84M -714M -40M -172M -326M -416M -39M 323M -43M
capitalExpenditure -2M -247 000 -13M -750 000 -3M -7M -59M -18M -8M -24M -93M -30M -57M -55M
freeCashFlow 106M -128M -100M -146M 311M -91M -773M -58M -180M -349M -509M -68M 265M -97M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-28 2023-02-28 2022-03-01 2021-03-01
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 0 -57M 0
netCashProvidedByInvestingActivities -204M -59M -93M 100M -378M
netDebtIssuance -4M -352M 82M -128M -96M
longTermNetDebtIssuance -4M -352M 82M -128M -96M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 263M 360M 249M 565M 1 075M
netCommonStockIssuance 263M 360M 249M 565M 876M
commonStockIssuance 263M 360M 249M 565M 876M
netPreferredStockIssuance 0 159 000 0 0 200M
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 1M -4M -6M 25M 5M
netCashProvidedByFinancingActivities 261M 4M 325M 462M 985M
incomeTaxesPaid 949 000 190 000 18M 13M 0
interestPaid 18M 17M 18M 19M 14M

Earning call transcript

2025 q3
2025-11-06 ET (fiscal 2025 q3)
2025 q2
2025-08-06 ET (fiscal 2025 q2)
2025 q1
2025-05-01 ET (fiscal 2025 q1)
2024 q4
2025-02-27 ET (fiscal 2024 q4)
2024 q3
2024-11-12 ET (fiscal 2024 q3)
2024 q2
2024-08-08 ET (fiscal 2024 q2)
2024 q1
2024-05-12 ET (fiscal 2024 q1)
2023 q4
2024-02-28 ET (fiscal 2023 q4)
2023 q3
2023-11-09 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-09 ET (fiscal 2023 q1)
2022 q4
2023-02-28 ET (fiscal 2022 q4)
2022 q3
2022-11-08 ET (fiscal 2022 q3)
2022 q2
2022-08-08 ET (fiscal 2022 q2)
2022 q1
2022-05-09 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-08-06 ET
Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights
2026-07-30 ET
Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026
2026-06-01 ET
Novavax to Participate in 2026 Jefferies Global Healthcare Conference
2026-05-07 ET
Novavax to Participate in BofA Securities 2026 Health Care Conference
2026-05-06 12:00 ET
Novavax Reports First Quarter 2026 Financial Results and Operational Highlights
2026-04-29 20:00 ET
Novavax to Report First Quarter 2026 Financial Results on May 6, 2026
2026-03-30 ET
Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development
2026-02-26 ET
Novavax to Participate in Upcoming Investor Conferences
2026-02-26 ET
Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
2026-02-19 ET
Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
2026-01-20 ET
Novavax Announces Entering into a License Agreement with Pfizer
2026-01-07 ET
Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference
2025-11-12 ET
Novavax to Participate in Jefferies London Healthcare Conference
2025-11-06 13:00 ET
Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights
2025-11-04 ET
Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment
2025-10-30 ET
Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025
2025-10-22 ET
Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy
2025-10-07 ET
Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment
2025-09-30 ET
Novavax Announces Progress on Sanofi Agreement
2025-09-04 ET
Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment
2025-09-03 ET
Novavax to Participate in the Cantor Global Healthcare Conference
2025-08-27 ET
Novavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.
2025-08-21 ET
Novavax Announces Convertible Debt Refinancing
2025-08-06 ET
Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights
2025-07-30 ET
Novavax to Report Second Quarter 2025 Financial Results on August 6, 2025
2025-07-24 ET
Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study
2025-06-11 ET
Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial
2025-05-29 ET
Novavax to Participate in Upcoming Investor Conferences
2025-05-19 ET
U.S. FDA Approves BLA for Novavax's COVID-19 Vaccine
2025-05-08 ET
Novavax Reports First Quarter 2025 Financial Results and Operational Highlights
2025-05-07 ET
Novavax to Participate in BofA Securities 2025 Health Care Conference
2025-05-05 ET
Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan
2025-05-01 ET
Novavax to Report First Quarter 2025 Financial Results on May 8, 2025
2025-04-29 ET
Novavax Appoints Charles Newton to Board of Directors
2025-04-15 ET
SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA
2025-03-11 ET
Novavax Announces Changes to Board of Directors
2025-02-27 ET
Novavax to Participate in Upcoming March Investor Conferences
2025-02-27 ET
Novavax Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
2025-02-20 ET
Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights on February 27, 2025
2025-01-23 ET
Brian Rosen, Commercial Strategy Senior Executive, Appointed as Director of Capstone Companies, Inc.
2024-12-13 ET
Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone
2024-12-10 ET
Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza
2024-12-04 ET
Novavax Announces Sale of Czech Republic Manufacturing Site to Novo Nordisk for $200 Million
2024-11-15 ET
Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)
2024-11-13 13:00 ET
Novavax to Participate in Jefferies London Healthcare Conference
2024-11-12 13:02 ET
Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights
2024-11-11 13:30 ET
U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
2024-11-04 21:30 ET
Novavax to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Operational Highlights on November 12, 2024
2024-10-16 12:14 ET
Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
2024-10-09 11:00 ET
Novavax's Updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine Receives Authorization in the EU
2024-09-25 12:00 ET
Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development
2024-09-04 13:25 ET
Novavax to Participate in Upcoming September Conferences
2024-08-30 19:46 ET
Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.
2024-08-08 12:02 ET
Novavax Reports Second Quarter 2024 Financial Results and Operational Highlights
2024-08-01 13:25 ET
Novavax to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Operational Highlights on August 8, 2024
2024-06-24 13:18 ET
Novavax Submits Application to European Medicines Agency for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine
2024-06-14 18:05 ET
Novavax Submits Application to U.S. FDA for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine
2024-05-30 13:25 ET
Novavax to Participate in 2024 Jefferies Global Healthcare Conference
2024-05-20 10:35 ET
Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meeting
2024-05-13 20:02 ET
Novavax to Participate in BofA Securities 2024 Health Care Conference
2024-05-10 06:15 ET
Novavax Reports First Quarter 2024 Financial Results and Operational Highlights
2024-05-10 06:00 ET
Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines
2024-05-07 13:25 ET
Novavax to Host Conference Call to Discuss First Quarter 2024 Financial Results and Operational Highlights on May 10, 2024
2024-05-06 10:22 ET
Shah Capital Launches Campaign Urging Stockholders to Vote AGAINST the Re-Election of All of Novavax’s Directors Up for Election at its 2024 Annual Meeting
2024-04-15 10:00 ET
Shah Capital nominates two highly qualified independent director candidates for Novavax
2024-04-01 12:00 ET
Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024
2024-02-29 21:02 ET
Novavax to Participate in TD Cowen's 44th Annual Health Care Conference
2024-02-28 13:00 ET
Novavax Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
2024-02-22 11:00 ET
Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase Agreement
2024-02-20 14:25 ET
Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights on February 28, 2024
2024-01-03 14:25 ET
Novavax to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-18 13:00 ET
Novavax's Updated COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan
2023-12-05 21:01 ET
Novavax's Updated COVID-19 Vaccine Now Authorized in Canada
2023-11-28 11:00 ET
Novavax's Updated Protein-based COVID-19 Vaccine Now an Option for All 194 Member States of the World Health Organization
2023-11-17 12:15 ET
Novavax Makes Changes to Executive Leadership Team to Enhance Focus on Delivery of Strategic Priorities
2023-11-10 14:25 ET
Novavax to Participate in Jefferies London Healthcare Conference
2023-11-09 13:00 ET
Novavax Reports Third Quarter 2023 Financial Results and Operational Highlights
2023-11-02 13:25 ET
Novavax to Host Conference Call to Discuss Third Quarter 2023 Financial Results and Operational Highlights on November 9, 2023
2023-10-31 20:37 ET
Novavax's Updated COVID-19 Vaccine Now Approved in the EU
2023-10-31 16:58 ET
Novavax's Updated Nuvaxovid™ COVID-19 Vaccine Receives Positive CHMP Opinion in the EU
2023-10-18 12:05 ET
Novavax Receives Full Marketing Authorization for Prototype COVID-19 Vaccine Nuvaxovid™ ▼ in United Kingdom
2023-10-18 12:00 ET
Novavax's Prototype COVID-19 Vaccine Nuvaxovid™ Receives Full Approval in Singapore
2023-10-13 13:29 ET
Novavax COVID-19 Vaccine Doses Available at Major Retail Pharmacies Across the U.S.
2023-10-11 12:00 ET
Novavax Advances Science Supporting Protein-based Vaccine Technology at IDWeek 2023 and World Vaccine Congress Europe 2023
2023-10-10 13:06 ET
Novavax Launches Choose to Protect™ Campaign to Educate Public About Importance of Updated COVID Vaccination this Fall
2023-10-03 19:50 ET
Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.
2023-09-08 20:31 ET
Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)
2023-09-08 16:00 ET
Novavax to Participate in Upcoming September Conferences
2023-08-22 11:00 ET
Novavax's Updated Protein-based XBB COVID Vaccine Induced Neutralizing Responses Against Emerging Subvariants, Including EG.5.1 and XBB.1.16.6
2023-08-08 12:00 ET
Novavax Reports Second Quarter 2023 Financial Results and Operational Highlights
2023-08-01 13:25 ET
Novavax to Host Conference Call to Discuss Second Quarter 2023 Financial Results and Operational Highlights on August 8, 2023
2023-07-06 13:47 ET
Novavax's Nuvaxovid™ Receives Full Marketing Authorization in the EU for the Prevention of COVID
2023-06-15 21:30 ET
Novavax Prepared to Deliver Protein-based Monovalent XBB COVID Vaccine Consistent with FDA VRBPAC Recommendation for the Fall
2023-06-15 13:05 ET
Novavax Announces Adjournment of 2023 Annual Meeting of Stockholders to July 11, 2023
2023-06-05 12:00 ET
Novavax Announces Agreement with Bill & Melinda Gates Medical Research Institute to Include Matrix-M™ Adjuvant as Potential Component in Vaccine Research
2023-06-01 20:02 ET
Novavax to Participate in the Jefferies Global Healthcare Conference
2023-05-26 13:29 ET
Novavax's Nuvaxovid™ Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU
2023-05-12 13:00 ET
Access to Novavax's COVID Vaccine Grows with Extended Interim Authorization for Adolescents in Singapore
2023-05-09 10:30 ET
Novavax Reports First Quarter 2023 Financial Results and Operational Highlights
2023-05-09 10:28 ET
Positive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses
2023-05-04 20:02 ET
Novavax to Participate in the BofA Securities 2023 Health Care Conference
2023-05-02 13:25 ET
Novavax to Host Conference Call to Discuss First Quarter 2023 Financial Results and Operational Highlights on May 9, 2023
2023-04-04 12:00 ET
Novavax Grows Presence at World Vaccine Congress 2023 and 33rd European Congress of Clinical Microbiology & Infectious Diseases
2023-03-06 21:02 ET
Novavax to Participate in TD Cowen's 43rd Annual Health Care Conference
2023-03-02 22:00 ET
Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)
2023-02-28 21:02 ET
Novavax Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
2023-02-21 21:02 ET
Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 28, 2023
2023-02-13 13:00 ET
U.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine
2023-01-25 22:00 ET
Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)
2023-01-18 13:00 ET
Novavax Nuvaxovid COVID-19 Vaccine Approved in South Korea as an Adult Booster
2023-01-09 14:00 ET
Novavax Names John C. Jacobs as New President & Chief Executive Officer
2022-12-30 13:00 ET
Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates
2022-12-28 22:00 ET
Novavax Announces Closing of $175.25 Million Offering of Convertible Senior Notes Due 2027 and $74.75 Million Public Offering of Common Stock
2022-12-16 04:45 ET
Novavax Announces Pricing of $150 Million Offering of Convertible Senior Notes
2022-12-16 04:45 ET
Novavax Announces Pricing of $65 Million Public Offering of Common Stock
2022-12-14 21:15 ET
Novavax Announces Proposed Offering of $125 Million of Convertible Senior Notes
2022-12-14 21:15 ET
Novavax Announces Proposed $125 Million Public Offering of Common Stock
2022-12-07 14:25 ET
Novavax Nuvaxovid COVID-19 Vaccine Approved in Canada for Use as a Primary Series in Adolescents
2022-12-02 14:15 ET
Novavax to Participate in BofA Securities 2022 Virtual Biotech SMID Cap Conference
2022-11-29 13:48 ET
World Health Organization Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Primary Series in Adolescents and as a Booster in Adults
2022-11-18 13:08 ET
Novavax Nuvaxovid COVID-19 Vaccine Receives Expanded Authorization in Canada as a Booster in Adults
2022-11-14 21:02 ET
Novavax to Participate in Jefferies London Healthcare Conference
2022-11-09 14:19 ET
Novavax Nuvaxovid™ COVID-19 Vaccine▼ Authorized in the United Kingdom for Use as a Booster in Adults
2022-11-08 21:02 ET
Novavax Reports Third Quarter 2022 Financial Results and Operational Highlights
2022-11-08 13:00 ET
Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster
2022-11-01 20:30 ET
Novavax Appoints Rick Rodgers to Board of Directors
2022-11-01 20:02 ET
Novavax to Host Conference Call to Discuss Third Quarter 2022 Financial Results and Operational Highlights on November 8, 2022
2022-10-20 18:15 ET
Novavax Showcases Data from Expanding Vaccine Portfolio at IDWeek 2022
2022-10-19 15:03 ET
U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster for Adults
2022-10-13 12:30 ET
Novavax COVID-19-Influenza Combination Vaccine Candidate Induced Antibody and T-Cell Responses Against SARS-CoV-2 and Homologous and Heterologous Influenza Strains
2022-10-12 12:30 ET
Novavax Prototype COVID-19 Vaccine Data Support Homologous and Heterologous Boosting and Suggest Benefit Against Variants
2022-10-10 12:00 ET
Novavax to Share New Data from Growing Vaccine Portfolio at World Vaccine Congress Europe 2022
2022-10-03 12:00 ET
Codexis Announces Appointment of Rahul Singhvi, Sc.D., to Board of Directors
2022-09-27 12:29 ET
Novavax Makes One Million Doses of Nuvaxovid™ Available for Use in the United Kingdom
2022-09-16 12:15 ET
Novavax Nuvaxovid™ COVID-19 Vaccine Receives Expanded Emergency Use Authorization in Taiwan for Use in Adolescents Aged 12 Through 17
2022-09-16 12:10 ET
Novavax Nuvaxovid™ COVID-19 Vaccine Now Available in Israel for Individuals Aged 12 and Older
2022-09-13 12:00 ET
Novavax and Serum Institute of India Announce Full Product Registration in South Africa of Novavax COVID-19 Vaccine as a Primary Series for Adults Aged 18 and Older
2022-09-12 13:23 ET
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the European Union for Use as a Booster for Adults Aged 18 and Older
2022-09-07 20:02 ET
Novavax to Participate in Upcoming September Conferences
2022-09-02 17:56 ET
Swissmedic Authorizes Novavax Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 Through 17 and as a Booster in Adults Aged 18 and Older
2022-09-01 17:37 ET
Novavax Nuvaxovid™ COVID-19 Vaccine Recommended by CHMP for Expanded Conditional Marketing Authorization in the European Union as a Booster for Adults Aged 18 and Older
2022-08-26 13:27 ET
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the United Kingdom for Use in Adolescents Aged 12 Through 17
2022-08-19 22:23 ET
U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Adolescents Aged 12 Through 17
2022-08-18 12:54 ET
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand for Adolescents Aged 12 Through 17
2022-08-17 12:00 ET
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand as a First and Second Booster for Adults
2022-08-15 12:00 ET
Novavax Submits Application to the U.S. FDA for Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults Aged 18 and Older
2022-08-12 13:22 ET
Novavax Nuvaxovid™ COVID-19 Vaccine Approved in South Korea for Use in Adolescents Aged 12 Through 17
2022-08-11 20:02 ET
Novavax to Participate in Fireside Chat at the SVB Securities Virtual Vaccine Forum
2022-08-08 20:02 ET
Novavax Reports Second Quarter 2022 Financial Results and Operational Highlights
2022-08-04 13:03 ET
Novavax Announces Initiation of Phase 2b/3 Hummingbird™ Global Clinical Trial for the Novavax COVID-19 Vaccine in Children Aged Six Months Through 11 Years
2022-08-01 20:02 ET
Novavax to Host Conference Call to Discuss Second Quarter 2022 Financial Results and Operational Highlights on August 8, 2022
2022-07-26 12:05 ET
Novavax Announces Expanded Approval of Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 through 17 in Japan
2022-07-26 12:00 ET
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Provisional Registration in Australia for Use in Adolescents Aged 12 Through 17
2022-07-19 20:28 ET
U.S. CDC Advisory Committee Unanimously Recommends Novavax COVID-19 Vaccine, Adjuvanted as a Primary Series for Individuals Aged 18 and Older
2022-07-19 12:35 ET
Novavax Announces Expanded Agreement with SK bioscience to Manufacture COVID-19 Vaccine Containing Omicron Variant and Manufacture the Novavax COVID-19 Vaccine in Prefilled Syringes
2022-07-13 21:34 ET
U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Individuals Aged 18 and Over
2022-07-11 12:10 ET
U.S. Government Secures 3.2 Million Doses of Novavax COVID-19 Vaccine
2022-07-05 13:30 ET
Novavax Nuvaxovid™ COVID-19 Vaccine Conditionally Authorized in the European Union for Adolescents Aged 12 Through 17
2022-06-28 22:41 ET
Novavax COVID-19 Data Presented at FDA VRBPAC Meeting Demonstrates Broad Antibody Responses to Both Prototype and Omicron-Specific Variants
2022-06-23 20:01 ET
Novavax' Nuvaxovid™ COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan for Use in Individuals Aged 18 and Over
2022-06-23 18:39 ET
Novavax COVID-19 Vaccine Nuvaxovid™ Recommended for Expanded Conditional Marketing Authorization in the European Union by CHMP for Adolescents Aged 12 Through 17
2022-06-13 11:00 ET
Novavax COVID-19 Vaccine Nuvaxovid™ Provisionally Registered in Australia as a Booster in Individuals Aged 18 and Over
2022-06-07 21:08 ET
FDA Advisory Committee Recommends Emergency Use Authorization of Novavax COVID-19 Vaccine for People Aged 18 Years and Older
2022-05-09 20:02 ET
Novavax Reports First Quarter 2022 Financial Results and Operational Highlights
2022-05-04 20:02 ET
Novavax to Participate in BofA Securities 2022 Healthcare Conference
2022-05-02 20:02 ET
Novavax to Host Conference Call to Discuss First Quarter 2022 Financial Results and Operational Highlights on May 9, 2022
2022-04-29 15:07 ET
FDA Announces Vaccines and Related Biological Products Advisory Committee Review of Novavax' COVID-19 Vaccine
2022-04-22 11:00 ET
Novavax Announces Initiation of COVID-19 Vaccine Booster Study in Adolescents in Phase 3 PREVENT-19 Trial
2022-04-20 16:41 ET
Initial Results from Novavax' COVID-19-Influenza Vaccine Trial are First to Show Feasibility of Combination Vaccine
2022-04-19 11:15 ET
Novavax Announces Approval of Nuvaxovid™ COVID-19 Vaccine for Primary and Booster Immunization in Japan
2022-04-18 13:35 ET
Novavax Grows Presence at World Vaccine Congress and 32nd European Congress of Clinical Microbiology & Infectious Diseases
2022-04-13 10:00 ET
Swissmedic Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine
2022-04-08 13:00 ET
Novavax and Serum Institute of India Receive Emergency Use Authorization for Novavax' COVID-19 Vaccine in Thailand
2022-03-31 10:00 ET
Novavax Submits Request to Expand Conditional Marketing Authorization of COVID-19 Vaccine in the European Union to Adolescents (Ages 12-17)
2022-03-25 12:30 ET
Novavax Announces Participation in Two Booster Studies Using its COVID-19 Vaccine
2022-03-22 20:02 ET
Novavax and Serum Institute of India Announce First Emergency Use Authorization of Novavax' COVID-19 Vaccine in Adolescents ≥12 to <18 in India
2022-03-10 14:00 ET
Novavax Announces Launch of Global Vaccine Education Programs
2022-03-02 21:02 ET
Novavax to Participate in Cowen's 42nd Annual Health Care Conference
2022-02-28 21:02 ET
Novavax Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
2022-02-28 21:01 ET
Novavax Announces Extended Durability of Protection Against Infection and Disease in United Kingdom COVID-19 Vaccine Phase 3 Clinical Trial
2022-02-21 21:01 ET
Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights on February 28, 2022
2022-02-17 16:35 ET
Health Canada Authorizes Novavax COVID-19 Vaccine
2022-02-14 21:02 ET
Singapore Health Sciences Authority Issues Interim Authorization for Novavax COVID-19 Vaccine
2022-02-14 14:01 ET
Novavax Files for Conditional Marketing Authorization of COVID-19 Vaccine in Switzerland
2022-02-11 14:25 ET
Novavax to Participate in Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference
2022-02-10 21:02 ET
Novavax Announces Positive Results of COVID-19 Vaccine in Pediatric Population of PREVENT-19 Phase 3 Clinical Trial
2022-02-03 22:33 ET
New Zealand's Medsafe Grants Provisional Approval for Novavax' COVID-19 Vaccine
2022-02-03 11:56 ET
Medicines and Healthcare Products Regulatory Agency Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine in Great Britain*
2022-01-31 18:42 ET
Novavax Submits Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine
2022-01-28 13:00 ET
Novavax and Israel Announce Advance Purchase Agreement for Supply of COVID-19 Vaccine
2022-01-19 23:21 ET
Australia Therapeutic Goods Administration (TGA) Grants Provisional Registration for Novavax COVID-19 Vaccine
2022-01-12 11:00 ET
South Korea Ministry of Food and Drug Safety Approves Novavax COVID-19 Vaccine
2022-01-10 13:39 ET
Novavax and Serum Institute of India File for Emergency Use Authorization of Novavax' COVID-19 Vaccine in South Africa
2022-01-04 21:02 ET
Novavax to Participate in the 40th Annual J.P. Morgan Healthcare Conference
2021-12-31 17:15 ET
Novavax Submits Final Data Packages to U.S. FDA as Prerequisite to Emergency Use Authorization Application Request for COVID-19 Vaccine
2021-12-28 14:29 ET
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in India
2021-12-23 23:30 ET
Novavax and SK bioscience Expand Manufacturing Agreement
2021-12-22 21:02 ET
Novavax Announces Initial Omicron Cross-Reactivity Data from COVID-19 Vaccine Booster and Adolescent Studies
2021-12-21 22:01 ET
Novavax Announces Initiation of PREVENT-19 COVID-19 Vaccine Phase 3 Trial Booster Study
2021-12-21 21:44 ET
World Health Organization SAGE Issues Interim Recommendations for Novavax COVID-19 Vaccine
2021-12-20 17:19 ET
World Health Organization Grants Second Emergency Use Listing for Novavax COVID-19 Vaccine
2021-12-20 15:59 ET
European Commission Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine
2021-12-20 13:25 ET
Novavax Receives Positive European Medicines Agency Recommendation for Conditional Marketing Authorization of its COVID-19 Vaccine
2021-12-17 15:37 ET
Novavax and Serum Institute of India Announce World Health Organization Grants Emergency Use Listing for NVX-CoV2373 COVID-19 Vaccine
2021-12-16 04:02 ET
Novavax Announces Submission of New Drug Application in Japan for Approval of COVID-19 Vaccine
2021-12-13 11:30 ET
Novavax Files for Emergency Use of COVID-19 Vaccine in the United Arab Emirates
2021-11-24 13:30 ET
Novavax Files for Interim Authorization of COVID-19 Vaccine in Singapore
2021-11-23 14:15 ET
Novavax to Participate in Evercore ISI's 4th Annual HealthCONx Virtual Conference
2021-11-17 14:26 ET
Novavax Confirms European Medicines Agency Review of COVID-19 Vaccine Filing for Conditional Marketing Authorization
2021-11-17 13:25 ET
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines
2021-11-15 13:45 ET
Novavax Announces Submission of Biologics License Application in South Korea for Approval of NVX-CoV2373
2021-11-04 20:02 ET
Novavax Reports Third Quarter 2021 Financial Results and Operational Highlights
2021-11-04 20:01 ET
Novavax Files COVID-19 Vaccine for Emergency Use Listing with World Health Organization
2021-11-03 13:30 ET
Novavax Files COVID-19 Vaccine for Provisional Approval in New Zealand
2021-11-01 10:22 ET
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia
2021-11-01 10:20 ET
Novavax Files for COVID-19 Vaccine Authorization with Health Canada and Completes Submission for Rolling Review to European Medicines Agency
2021-10-29 11:15 ET
Novavax Files for Provisional Approval of its COVID-19 Vaccine in Australia
2021-10-27 12:30 ET
Novavax Files for Authorization of its COVID-19 Vaccine in the United Kingdom
2021-10-18 13:15 ET
Novavax to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights on November 4, 2021
2021-10-15 20:05 ET
Novavax to Participate in World Vaccine Congress Europe
2021-10-04 20:05 ET
Novavax Announces Leadership Appointment and Updates
2021-09-29 20:05 ET
Novavax to Participate in Health Equity and Vaccine Confidence Panel at Maryland Life Sciences Bio Innovation Conference
2021-09-24 12:59 ET
Novavax Hosts HM King Carl XVI Gustaf and HM Queen Silvia of Sweden During Royal Visit to Uppsala County
2021-09-24 00:03 ET
Results from Novavax NanoFlu Influenza Vaccine Phase 3 Clinical Trial Published in The Lancet Infectious Diseases
2021-09-23 13:25 ET
Novavax and Serum Institute of India Announce Submission to World Health Organization for Emergency Use Listing of Novavax' COVID-19 Vaccine
2021-09-23 13:15 ET
Novavax to Participate in Fireside Chat at the 2021 Cantor Virtual Global Healthcare Conference
2021-09-20 20:05 ET
Novavax to Participate in Fireside Chat at Devex @ UNGA 76
2021-09-16 23:02 ET
Novavax to Participate in University of Oxford Com-COV3 Study Comparing Mixed COVID-19 Vaccine Schedule in Adolescents
2021-09-09 13:25 ET
Novavax to Participate in Upcoming September Conferences
2021-09-08 12:16 ET
Novavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine for COVID-19 and Seasonal Influenza
2021-09-07 13:05 ET
Novavax to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021
2021-08-30 20:07 ET
Novavax Statement on CDC Guidance Update for COVID-19 Clinical Trial Participants
2021-08-25 13:27 ET
Novavax to Participate in OCTAVE-DUO Study to Evaluate Third Dose of Vaccine in Participants with Impaired Immune Systems
2021-08-16 12:50 ET
Novavax Appoints Biopharmaceutical Veterans Jim Kelly as Chief Financial Officer and Nasir Egal, Ph.D., as Senior Vice President of Quality Assurance
2021-08-05 20:05 ET
Novavax Reports Second Quarter 2021 Financial Results and Operational Highlights
2021-08-05 20:04 ET
Novavax Announces COVID-19 Vaccine Booster Data Demonstrating Four-Fold Increase in Neutralizing Antibody Levels Versus Peak Responses After Primary Vaccination
2021-08-05 20:03 ET
Novavax and Serum Institute of India Announce Submission to Regulatory Agencies in India, Indonesia, Philippines for Emergency Use Authorization of Novavax' Recombinant Nanoparticle COVID-19 Vaccine
2021-08-04 13:10 ET
Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 Vaccine
2021-07-06 12:30 ET
Novavax to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights on August 5, 2021
2021-06-30 21:26 ET
Novavax Publishes Results of United Kingdom Phase 3 Clinical Trial in New England Journal of Medicine, Demonstrating High Levels of Efficacy of COVID-19 Vaccine
2021-06-17 20:02 ET
Novavax to Participate in Fireside Chat at SVB Leerink CybeRx Series: Vaccine Forum
2021-06-17 13:22 ET
Novavax to Participate in National Vaccine Advisory Committee Meeting
2021-06-14 20:05 ET
Novavax Announces Positive Results from First Study of Influenza Vaccine and COVID-19 Vaccine Candidate Administered Simultaneously
2021-06-14 10:00 ET
Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
2021-06-11 20:05 ET
Novavax Announces Positive Data from Three Complementary Studies of COVID-19 Beta (B.1.351) Variant Strain Vaccine
2021-06-09 13:03 ET
Novavax to Host Maryland Governor Larry Hogan at Site of Future Novavax Vaccines Innovation Campus and Global Headquarters
2021-06-07 20:05 ET
Novavax to Participate in Panel at BIO Digital 2021
2021-05-27 12:30 ET
Novavax to Participate in Jefferies Virtual Healthcare Conference
2021-05-24 21:03 ET
Novavax to Present at International Society for Vaccines Virtual Congress COVID-19 Vaccine Update
2021-05-22 16:20 ET
Novavax Announces Memorandum of Understanding to Explore Expansion of COVID-19 Vaccine Activities in South Korea
2021-05-21 12:53 ET
Novavax Honored by Maryland Tech Council During 2021 Industry Awards Celebration
2021-05-10 20:02 ET
Novavax Reports First Quarter 2021 Financial Results and Operational Highlights
2021-05-10 13:12 ET
Novavax Announces Positive Preclinical Data for Combination Influenza and COVID-19 Vaccine Candidate
2021-05-06 13:05 ET
Novavax and Gavi Execute Advance Purchase Agreement for COVID-19 Vaccine for COVAX Facility
2021-05-05 21:03 ET
New England Journal of Medicine Publishes Phase 2b Clinical Trial Results Demonstrating Efficacy of Novavax COVID-19 Vaccine Against the B.1.351 Variant
2021-05-03 12:51 ET
Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine
2021-04-23 20:02 ET
Novavax to Host Conference Call to Discuss First Quarter Financial Results and Operational Highlights on May 10, 2021
2021-04-23 09:00 ET
Malaria Vaccine Phase 2b Clinical Trial Results Published in Preprints with The Lancet
2021-04-14 21:39 ET
Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations
2021-04-13 21:34 ET
Novavax Announces Leadership Updates
2021-04-08 12:05 ET
Novavax to Participate in Fireside Chat at Goldman Sachs Virtual Conference
2021-04-05 20:05 ET
Novavax Initiates COVID-19 Vaccine Clinical Trial Crossover
2021-04-05 12:50 ET
Novavax CEO Stan Erck to Participate in Longwood Healthcare Leaders Meeting
2021-03-29 20:02 ET
GSK to support manufacture of Novavax' COVID-19 vaccine
2021-03-11 21:02 ET
Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in United Kingdom and South Africa Trials
2021-03-08 23:00 ET
Novavax to Participate in H.C. Wainwright Virtual Global Life Sciences Conference Fireside Chat
2021-03-01 21:02 ET
Novavax Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
2021-02-26 13:22 ET
Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan
2021-02-22 12:00 ET
Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico
2021-02-22 12:00 ET
Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico
2021-02-18 21:02 ET
Novavax Announces Memorandum of Understanding with Gavi for Cumulative Supply to COVAX Facility of 1.1 Billion Doses of COVID-19 Vaccine
2021-02-18 21:02 ET
Novavax Announces Memorandum of Understanding with Gavi for Cumulative Supply to COVAX Facility of 1.1 Billion Doses of COVID-19 Vaccine
2021-02-16 13:00 ET
Novavax to Host Conference Call to Discuss Fourth Quarter Financial Results and Operational Highlights on March 1, 2021
2021-02-16 01:04 ET
Novavax Announces Expanded Collaboration and License Agreement with SK Bioscience for 40 Million Doses of COVID-19 Vaccine for South Korea
2021-02-16 01:04 ET
Novavax Announces Expanded Collaboration and License Agreement with SK Bioscience for 40 Million Doses of COVID-19 Vaccine for South Korea
2021-02-04 21:05 ET
Novavax Announces Start of Rolling Review by Multiple Regulatory Authorities for COVID-19 Vaccine Authorization
2021-02-04 21:05 ET
Novavax Announces Start of Rolling Review by Multiple Regulatory Authorities for COVID-19 Vaccine Authorization
2021-02-04 02:14 ET
Novavax and Government of Switzerland Announce Agreement in Principle to Supply COVID-19 Vaccine
2021-02-04 02:14 ET
Novavax and Government of Switzerland Announce Agreement in Principle to Supply COVID-19 Vaccine
2021-02-02 17:31 ET
Novavax Announces Memorandum of Understanding to Produce COVID-19 Vaccine Made in Canada
2021-02-02 00:32 ET
Novavax to Present COVID-19 Vaccine Candidate Data at New York Academy of Science
2021-01-28 21:05 ET
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial
2021-01-28 21:05 ET
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial
2021-01-22 22:22 ET
Novavax and Government of Canada Finalize Advance Purchase Agreement for COVID-19 Vaccine
2021-01-22 21:49 ET
Novavax Names Madelyn Caltabiano Senior Vice President, Global Program Management
2021-01-15 13:00 ET
Regulatory Expert Henrietta Ukwu, M.D. Appointed Novavax Chief Regulatory and Quality Officer
2021-01-15 13:00 ET
Regulatory Expert Henrietta Ukwu, M.D. Appointed Novavax Chief Regulatory and Quality Officer
2021-01-07 23:14 ET
Novavax Finalizes Agreement with Commonwealth of Australia for 51 Million Doses of COVID-19 Vaccine
2021-01-07 23:14 ET
Novavax Finalizes Agreement with Commonwealth of Australia for 51 Million Doses of COVID-19 Vaccine
2021-01-06 14:00 ET
Novavax to Participate in Upcoming Conferences
2020-12-28 14:20 ET
Novavax Announces Initiation of PREVENT-19 Pivotal Phase 3 Efficacy Trial of COVID-19 Vaccine in the United States and Mexico
2020-12-28 14:20 ET
Novavax Announces Initiation of PREVENT-19 Pivotal Phase 3 Efficacy Trial of COVID-19 Vaccine in the United States and Mexico
2020-12-21 22:42 ET
Biopharma Executive Rick Crowley Joins Novavax as Chief Operations Officer
2020-12-17 00:07 ET
Novavax Announces Agreement with Government of New Zealand for 10.7 Million Doses of COVID-19 Vaccine
2020-12-17 00:07 ET
Novavax Announces Agreement with Government of New Zealand for 10.7 Million Doses of COVID-19 Vaccine
2020-12-09 13:02 ET
Novavax Appoints Vaccine Industry Expert Margaret G. McGlynn to Board of Directors
2020-12-09 13:02 ET
Novavax Appoints Vaccine Industry Expert Margaret G. McGlynn to Board of Directors
2020-11-30 11:30 ET
Novavax Announces COVID-19 Vaccine Clinical Development Progress
2020-11-30 11:30 ET
Novavax Announces COVID-19 Vaccine Clinical Development Progress
2020-11-25 21:15 ET
Novavax to Participate in Upcoming Conferences
2020-11-10 14:18 ET
Novavax to Host Conference Call for Questions Related to Third Quarter Financial and Operating Results on November 10, 2020
2020-11-10 14:18 ET
Novavax to Host Conference Call for Questions Related to Third Quarter Financial and Operating Results on November 10, 2020
2020-11-09 21:05 ET
Novavax Reports Third Quarter 2020 Financial and Operational Results
2020-11-09 21:05 ET
Novavax Reports Third Quarter 2020 Financial and Operational Results
2020-11-09 21:02 ET
Novavax Appoints Gregory F. Covino as Chief Financial Officer and Announces Leadership Updates
2020-11-09 21:02 ET
Novavax Appoints Gregory F. Covino as Chief Financial Officer and Announces Leadership Updates
2020-11-09 13:30 ET
Novavax COVID-19 Vaccine Granted Fast Track Designation by U.S. FDA
2020-11-09 13:30 ET
Novavax COVID-19 Vaccine Granted Fast Track Designation by U.S. FDA
2020-11-04 14:52 ET
Novavax and Commonwealth of Australia Announce Agreement in Principle for Acquisition of Novavax COVID-19 Vaccine
2020-11-04 14:51 ET
Novavax and Commonwealth of Australia Announce Agreement in Principle for Acquisition of Novavax COVID-19 Vaccine
2020-11-03 22:32 ET
Novavax Appoints Biopharmaceutical Industry Veteran Gregg Alton to Board of Directors
2020-11-03 22:32 ET
Novavax Appoints Biopharmaceutical Industry Veteran Gregg Alton to Board of Directors
2020-11-03 13:00 ET
Novavax to Host Conference Call to Discuss Third Quarter Financial and Operating Results on November 9, 2020
2020-11-03 13:00 ET
Novavax to Host Conference Call to Discuss Third Quarter Financial and Operating Results on November 9, 2020
2020-11-02 13:16 ET
Novavax Announces Facility Expansion to Support Global Vaccine Development
2020-10-27 13:03 ET
Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update
2020-10-27 13:02 ET
Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update
2020-10-20 12:30 ET
Novavax to Present COVID-19 Vaccine Data at World Vaccine Congress Europe 2020
2020-10-20 12:30 ET
Novavax to Present COVID-19 Vaccine Data at World Vaccine Congress Europe 2020
2020-10-13 12:00 ET
Novavax Appoints Leadership Team to Advance NanoFlu through Regulatory Licensure
2020-10-13 12:00 ET
Novavax Appoints Leadership Team to Advance NanoFlu through Regulatory Licensure
2020-10-05 13:00 ET
Novavax to Participate in Upcoming Conferences
2020-10-05 13:00 ET
Novavax to Participate in Upcoming Conferences
2020-09-28 13:00 ET
Novavax to Present COVID-19, Influenza and RSV Candidate Vaccine Data at World Vaccine Congress Washington 2020
2020-09-28 13:00 ET
Novavax to Present COVID-19, Influenza and RSV Candidate Vaccine Data at World Vaccine Congress Washington 2020
2020-09-25 11:00 ET
Endo Announces Fill-Finish Manufacturing and Services Agreement for Novavax COVID-19 Vaccine Candidate
2020-09-24 20:35 ET
Gov. Hogan, Novavax’ Erck, & BIO’s Dr. McMurry-Heath Toured Novavax Labs and Discussed Progress on COVID-19 Vaccine
2020-09-24 20:29 ET
Gov. Hogan, Novavax’ Erck, & BIO’s Dr. McMurry-Heath Toured Novavax Labs and Discussed Progress on COVID-19 Vaccine
2020-09-24 20:05 ET
Novavax Initiates Phase 3 Efficacy Trial of COVID-19 Vaccine in the United Kingdom
2020-09-24 20:05 ET
Novavax Initiates Phase 3 Efficacy Trial of COVID-19 Vaccine in the United Kingdom
2020-09-15 11:00 ET
Novavax Announces COVID-19 Vaccine Manufacturing Agreement with Serum Institute of India, Increasing Novavax’ Global Production Capacity to Over 2 Billion Doses Annually
2020-09-15 11:00 ET
Novavax Announces COVID-19 Vaccine Manufacturing Agreement with Serum Institute of India, Increasing Novavax’ Global Production Capacity to Over 2 Billion Doses Annually
2020-09-10 11:00 ET
Novavax to Participate in Upcoming Investor Conferences
2020-09-10 11:00 ET
Novavax to Participate in Upcoming Investor Conferences
2020-09-08 10:30 ET
Biopharma Leaders Unite to Stand with Science
2020-09-02 21:14 ET
Novavax Announces Publication of Phase 1 Data for COVID-19 Vaccine Candidate in The New England Journal of Medicine
2020-09-02 21:14 ET
Novavax Announces Publication of Phase 1 Data for COVID-19 Vaccine Candidate in The New England Journal of Medicine
2020-08-31 12:55 ET
Novavax and Canada Reach Agreement in Principle to Acquire Novavax’ COVID-19 Vaccine
2020-08-31 12:55 ET
Novavax and Canada Reach Agreement in Principle to Acquire Novavax’ COVID-19 Vaccine
2020-08-24 13:00 ET
Novavax Initiates Phase 2 Portion of Phase 1/2 Clinical Trial of COVID-19 Vaccine
2020-08-24 13:00 ET
Novavax Initiates Phase 2 Portion of Phase 1/2 Clinical Trial of COVID-19 Vaccine
2020-08-17 06:30 ET
Novavax Initiates Efficacy Trial of COVID-19 Vaccine in South Africa
2020-08-17 06:30 ET
Novavax Initiates Efficacy Trial of COVID-19 Vaccine in South Africa
2020-08-14 05:07 ET
Novavax and UK Government Announce Collaboration and Purchase Agreement for Novavax’ COVID-19 Vaccine Candidate
2020-08-14 05:07 ET
Novavax and UK Government Announce Collaboration and Purchase Agreement for Novavax’ COVID-19 Vaccine Candidate
2020-08-13 12:30 ET
Novavax and SK bioscience Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate
2020-08-13 12:30 ET
Novavax and SK bioscience Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate
2020-08-10 20:05 ET
AGC Biologics Expands Partnership with Novavax
2020-08-10 20:02 ET
Novavax Reports Second Quarter 2020 Financial and Operational Results
2020-08-10 20:02 ET
Novavax Reports Second Quarter 2020 Financial and Operational Results
2020-08-07 09:28 ET
Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan
2020-08-07 09:26 ET
Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan
2020-08-07 09:26 ET
Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan
2020-08-06 20:50 ET
Novavax and Serum Institute of India Announce Development and Commercial Collaboration
2020-08-06 20:49 ET
Novavax and Serum Institute of India Announce Development and Commercial Collaboration
2020-08-06 10:45 ET
Novavax to Host Conference Call to Discuss Second Quarter Financial and Operating Results on August 10, 2020
2020-08-06 10:45 ET
Novavax to Host Conference Call to Discuss Second Quarter Financial and Operating Results on August 10, 2020
2020-08-04 20:05 ET
Novavax Announces Positive Phase 1 Data for its COVID-19 Vaccine Candidate
2020-08-04 20:05 ET
Novavax Announces Positive Phase 1 Data for its COVID-19 Vaccine Candidate
2020-07-23 20:04 ET
Novavax and FUJIFILM Diosynth Biotechnologies Initiate Large Scale Manufacturing of COVID-19 Vaccine Candidate
2020-07-23 20:02 ET
Novavax and FUJIFILM Diosynth Biotechnologies Initiate Large Scale Manufacturing of COVID-19 Vaccine Candidate
2020-07-23 20:02 ET
Novavax and FUJIFILM Diosynth Biotechnologies Initiate Large Scale Manufacturing of COVID-19 Vaccine Candidate
2020-07-20 20:05 ET
Novavax to Present COVID-19 Vaccine Candidate Progress at 2nd ISV COVID-19 Vaccines Virtual Congress
2020-07-20 20:05 ET
Novavax to Present COVID-19 Vaccine Candidate Progress at 2nd ISV COVID-19 Vaccines Virtual Congress
2020-07-07 10:00 ET
Novavax Announces $1.6 Billion Funding from Operation Warp Speed
2020-07-07 10:00 ET
Novavax Announces $1.6 Billion Funding from Operation Warp Speed
2020-07-02 12:30 ET
Novavax Announces Updates to Leadership Team
2020-07-02 12:30 ET
Novavax Announces Updates to Leadership Team
2020-06-29 12:42 ET
Novavax Expands Executive Leadership and Announces Key Promotions
2020-06-29 12:42 ET
Novavax Expands Executive Leadership and Announces Key Promotions
2020-06-24 12:00 ET
Novavax to Participate in H.C. Wainwright Fireside Chat Series
2020-06-24 12:00 ET
Novavax to Participate in H.C. Wainwright Fireside Chat Series
2020-06-17 12:00 ET
Novavax Announces Additions to Executive Leadership
2020-06-17 12:00 ET
Novavax Announces Additions to Executive Leadership
2020-06-16 12:00 ET
Novavax Appoints Biotechnology Veteran David Mott to Board of Directors
2020-06-16 12:00 ET
Novavax Appoints Biotechnology Veteran David Mott to Board of Directors
2020-06-15 14:09 ET
Novavax to Raise $200 Million from Private Placement with RA Capital
2020-06-15 14:09 ET
Novavax to Raise $200 Million from Private Placement with RA Capital
2020-06-08 20:05 ET
Novavax President of R&D Dr. Gregory Glenn to Discuss the Development of COVID-19 Vaccines on Panel at 2020 BIO Digital
2020-06-08 20:05 ET
Novavax President of R&D Dr. Gregory Glenn to Discuss the Development of COVID-19 Vaccines on Panel at 2020 BIO Digital
2020-06-05 00:04 ET
Novavax Awarded Department of Defense Contract for COVID-19 Vaccine
2020-06-05 00:04 ET
Novavax Awarded Department of Defense Contract for COVID-19 Vaccine
2020-05-27 12:00 ET
Novavax Expands Large-Scale Global Manufacturing Capacity
2020-05-27 12:00 ET
Novavax Expands Large-Scale Global Manufacturing Capacity
2020-05-25 20:30 ET
Novavax Initiates Phase 1/2 Clinical Trial of COVID-19 Vaccine
2020-05-25 20:30 ET
Novavax Initiates Phase 1/2 Clinical Trial of COVID-19 Vaccine
2020-05-11 20:05 ET
Novavax Reports First Quarter 2020 Financial Results
2020-05-11 20:05 ET
Novavax Reports First Quarter 2020 Financial Results
2020-05-11 20:02 ET
Novavax to Receive up to $388 Million Funding from CEPI for COVID-19 Vaccine Development and Manufacturing
2020-05-11 20:02 ET
Novavax to Receive up to $388 Million Funding from CEPI for COVID-19 Vaccine Development and Manufacturing
2020-05-11 15:53 ET
Novavax to Present COVID-19 Vaccine Candidate Progress in World Vaccine Congress Webinar Series
2020-05-11 15:52 ET
Novavax to Present COVID-19 Vaccine Candidate Progress in World Vaccine Congress Webinar Series
2020-05-06 13:15 ET
Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 11, 2020
2020-05-06 13:15 ET
Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 11, 2020
2020-04-08 10:00 ET
Novavax Identifies Coronavirus Vaccine Candidate; Accelerates Initiation of First-in-Human Trial to Mid-May
2020-04-08 10:00 ET
Novavax Identifies Coronavirus Vaccine Candidate; Accelerates Initiation of First-in-Human Trial to Mid-May
2020-03-24 10:00 ET
Novavax’ NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial
2020-03-24 10:00 ET
Novavax’ NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial
2020-03-11 20:17 ET
Novavax Reports Fourth Quarter and Full Year 2019 Financial Results
2020-03-11 14:45 ET
Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate
2020-03-10 09:30 ET
Novavax Awarded Funding from CEPI for COVID-19 Vaccine Development
2020-03-05 21:05 ET
Novavax to Host Conference Call to Discuss Fourth Quarter Financial Results on March 11, 2020
2020-02-26 14:27 ET
Novavax Advances Development of Novel COVID-19 Vaccine
2020-02-25 21:05 ET
Novavax’ Preclinical NanoFlu Data Published in Vaccines; Details Structural Basis for Broadly Neutralizing Immunity
2020-01-15 13:30 ET
Novavax Granted Fast Track Designation for NanoFlu in Older Adults
2020-01-09 21:05 ET
Novavax to Present at the 38th Annual J.P. Morgan Healthcare Conference
2019-11-07 21:05 ET
Novavax Reports Third Quarter 2019 Financial Results
2019-10-31 20:05 ET
Novavax to Host Conference Call to Discuss Third Quarter Financial Results on November 7, 2019
2019-10-15 11:00 ET
Novavax Initiates Pivotal Phase 3 Clinical Trial of NanoFlu Influenza Vaccine in Older Adults
2019-09-19 11:00 ET
Novavax to Present at the Ladenburg Thalmann 2019 Healthcare Conference
2019-04-09 20:05 ET
Novavax Scientific Leadership to Present RSV Maternal Immunization Program Phase 3 Data and Participate in Panel on COPD at World Vaccine Congress
2019-03-18 20:05 ET
Novavax Reports Fourth Quarter and Year-End 2018 Financial Results
2019-03-11 16:21 ET
Novavax to Host Conference Call to Discuss Fourth Quarter and Year-End 2018 Financial Results on March 18, 2019
2019-02-28 12:00 ET
Novavax Announces Topline Results from Phase 3 PrepareTM Trial of ResVax™ for Prevention of RSV Disease in Infants via Maternal Immunization
2019-01-03 21:05 ET
Novavax Announces Positive Phase 2 NanoFlu Results in Older Adults

SEC forms

Show financial reports only

SEC form 10
2026-11-05 00:00 ET
Novavax reported for 2026 q3
SEC form 8
2026-11-05 00:00 ET
Novavax published news for 2026 q3
SEC form 8
2026-11-05 00:00 ET
Novavax reported for 2026 q3
SEC form 8
2026-08-06 12:03 ET
Novavax published news for 2026 q2
SEC form 8
2026-08-06 12:03 ET
Novavax published news for 2026 q2
SEC form 10
2026-08-06 11:50 ET
Novavax reported for 2026 q2
SEC form 8
2026-05-06 12:00 ET
Novavax published news for 2026 q1
SEC form 8
2026-05-06 12:00 ET
Novavax reported for 2026 q1
SEC form 10
2026-05-06 11:50 ET
Novavax published news for 2026 q1
SEC form 8
2026-02-26 08:02 ET
Novavax published news for 2025 q4
SEC form 8
2026-02-26 08:02 ET
Novavax reported for 2025 q4
SEC form 10
2026-02-26 07:33 ET
Novavax reported for 2025 q4
SEC form 8
2026-01-12 13:01 ET
Novavax published news for 2025 q4
SEC form 8
2026-01-12 13:01 ET
Novavax published news for 2025 q4
SEC form 8
2025-11-06 08:00 ET
Novavax published news for 2025 q3
SEC form 8
2025-11-06 08:00 ET
Novavax reported for 2025 q3
SEC form 10
2025-11-06 07:47 ET
Novavax reported for 2025 q3
SEC form 8
2025-11-04 06:02 ET
Novavax published news for 2025 q3
SEC form 8
2025-11-04 06:02 ET
Novavax published news for 2025 q3
SEC form 8
2025-10-07 11:00 ET
Novavax published news for 2025 q3
SEC form 8
2025-10-07 11:00 ET
Novavax published news for 2025 q3
SEC form 8
2025-08-27 20:38 ET
Novavax published news for 2025 q2
SEC form 8
2025-08-27 20:38 ET
Novavax published news for 2025 q2
SEC form 8
2025-08-06 12:04 ET
Novavax published news for 2025 q2
SEC form 8
2025-08-06 12:04 ET
Novavax reported for 2025 q2
SEC form 10
2025-08-06 11:47 ET
Novavax reported for 2025 q2
SEC form 8
2025-06-11 11:01 ET
Novavax published news for 2025 q1
SEC form 8
2025-06-11 11:01 ET
Novavax published news for 2025 q1
SEC form 8
2025-06-11 11:01 ET
Novavax published news for 2025 q1
SEC form 8
2025-05-08 12:26 ET
Novavax published news for 2025 q1
SEC form 8
2025-05-08 12:26 ET
Novavax reported for 2025 q1
SEC form 10
2025-05-08 11:59 ET
Novavax published news for 2025 q1
SEC form 10
2025-05-08 00:00 ET
Novavax published news for 2025 q1
SEC form 8
2025-03-04 13:01 ET
Novavax published news for 2024 q4
SEC form 8
2025-03-04 13:01 ET
Novavax published news for 2024 q4
SEC form 8
2025-02-27 08:05 ET
Novavax published news for 2024 q4
SEC form 8
2025-02-27 08:05 ET
Novavax reported for 2024 q4
SEC form 10
2025-02-27 07:41 ET
Novavax reported for 2024 q4
SEC form 10
2025-02-27 00:00 ET
Novavax reported for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Novavax published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Novavax published news for 2024 q4
SEC form 10
2024-11-12 16:08 ET
Novavax reported for 2024 q3
SEC form 8
2024-11-12 08:04 ET
Novavax published news for 2024 q3
SEC form 8
2024-11-12 08:04 ET
Novavax reported for 2024 q3
SEC form 10
2024-11-12 00:00 ET
Novavax reported for 2024 q3
SEC form 8
2024-08-08 08:04 ET
Novavax published news for 2024 q2
SEC form 8
2024-08-08 08:04 ET
Novavax reported for 2024 q2
SEC form 10
2024-08-08 07:37 ET
Novavax reported for 2024 q2
SEC form 10
2024-08-08 00:00 ET
Novavax reported for 2024 q2
SEC form 10
2024-05-10 00:00 ET
Novavax published news for 2024 q1
SEC form 8
2024-05-10 00:00 ET
Novavax published news for 2024 q1
SEC form 8
2024-05-10 00:00 ET
Novavax reported for 2024 q1
SEC form 8
2024-02-28 08:07 ET
Novavax published news for 2023 q4
SEC form 8
2024-02-28 08:07 ET
Novavax reported for 2023 q4
SEC form 10
2024-02-28 07:30 ET
Novavax reported for 2023 q4
SEC form 10
2024-02-28 00:00 ET
Novavax reported for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Novavax published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Novavax published news for 2023 q4
SEC form 8
2023-11-09 08:05 ET
Novavax reported for 2023 q3
SEC form 10
2023-11-09 07:32 ET
Novavax reported for 2023 q3
SEC form 10
2023-11-09 00:00 ET
Novavax reported for 2023 q3
SEC form 6
2023-08-08 08:05 ET
Novavax reported for 2023 q2
SEC form 6
2023-08-08 07:56 ET
Novavax published news for 2023 q2
SEC form 6
2023-08-08 07:20 ET
Novavax published news for 2023 q2
SEC form 10
2023-08-08 06:30 ET
Novavax reported for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Novavax reported for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Novavax reported for 2023 q2
SEC form 6
2023-07-11 17:12 ET
Novavax published news for 2023 q2
SEC form 6
2023-07-07 16:01 ET
Novavax published news for 2023 q2
SEC form 6
2023-06-21 16:39 ET
Novavax published news for 2023 q1
SEC form 10
2023-05-09 00:00 ET
Novavax published news for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Novavax published news for 2023 q1
SEC form 6
2023-04-04 16:34 ET
Novavax published news for 2023 q1
SEC form 6
2023-03-22 17:00 ET
Novavax published news for 2022 q4
SEC form 6
2023-03-14 08:41 ET
Novavax published news for 2022 q4
SEC form 6
2023-03-03 17:00 ET
Novavax published news for 2022 q4
SEC form 6
2023-03-02 17:29 ET
Novavax published news for 2022 q4
SEC form 10
2023-02-28 16:27 ET
Novavax reported for 2022 q4
SEC form 6
2023-02-28 16:08 ET
Novavax published news for 2022 q4
SEC form 10
2023-02-28 00:00 ET
Novavax reported for 2022 q4
SEC form 8
2023-02-28 00:00 ET
Novavax reported for 2022 q4
SEC form 6
2023-01-25 17:03 ET
Novavax published news for 2022 q4
SEC form 6
2023-01-09 09:06 ET
Novavax published news for 2022 q4
SEC form 6
2022-12-28 17:00 ET
Novavax published news for 2022 q3
SEC form 6
2022-12-21 08:00 ET
Novavax published news for 2022 q3
SEC form 6
2022-12-19 16:29 ET
Novavax published news for 2022 q3
SEC form 6
2022-12-14 17:27 ET
Novavax published news for 2022 q3
SEC form 6
2022-12-09 17:00 ET
Novavax published news for 2022 q3
SEC form 6
2022-11-21 17:15 ET
Novavax published news for 2022 q3
SEC form 10
2022-11-09 09:01 ET
Novavax reported for 2022 q3
SEC form 10
2022-11-09 00:00 ET
Novavax reported for 2022 q3
SEC form 6
2022-11-08 16:12 ET
Novavax published news for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Novavax reported for 2022 q3
SEC form 6
2022-11-01 17:07 ET
Novavax published news for 2022 q3
SEC form 6
2022-11-01 17:00 ET
Novavax published news for 2022 q3
SEC form 6
2022-10-06 17:03 ET
Novavax published news for 2022 q3
SEC form 6
2022-08-09 17:06 ET
Novavax published news for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Novavax reported for 2022 q2
SEC form 8
2022-08-09 00:00 ET
Novavax reported for 2022 q2
SEC form 10
2022-08-08 19:37 ET
Novavax reported for 2022 q2
SEC form 6
2022-07-11 17:00 ET
Novavax published news for 2022 q2
SEC form 6
2022-06-21 16:16 ET
Novavax published news for 2022 q1
SEC form 6
2022-05-10 17:00 ET
Novavax published news for 2022 q1
SEC form 10
2022-05-10 00:00 ET
Novavax reported for 2022 q1
SEC form 8
2022-05-10 00:00 ET
Novavax reported for 2022 q1
SEC form 10
2022-05-09 19:11 ET
Novavax reported for 2022 q1
SEC form 6
2022-05-02 17:01 ET
Novavax published news for 2022 q1
SEC form 6
2022-04-20 17:01 ET
Novavax published news for 2022 q1
SEC form 6
2022-04-20 13:35 ET
Novavax published news for 2022 q1
SEC form 6
2022-03-07 17:00 ET
Novavax published news for 2021 q4
SEC form 6
2022-03-01 17:16 ET
Novavax published news for 2021 q4
SEC form 10
2022-03-01 00:00 ET
Novavax published news for 2021 q4
SEC form 8
2022-03-01 00:00 ET
Novavax published news for 2021 q4
SEC form 10
2022-02-28 21:13 ET
Novavax published news for 2021 q4
SEC form 6
2022-02-10 16:29 ET
Novavax published news for 2021 q4
SEC form 6
2022-02-07 17:00 ET
Novavax published news for 2021 q4
SEC form 6
2022-01-10 08:47 ET
Novavax published news for 2021 q4
SEC form 6
2021-12-30 17:16 ET
Novavax published news for 2021 q3
SEC form 6
2021-12-20 16:05 ET
Novavax published news for 2021 q3
SEC form 6
2021-11-05 17:00 ET
Novavax published news for 2021 q3
SEC form 10
2021-11-05 00:00 ET
Novavax published news for 2021 q3
SEC form 8
2021-11-05 00:00 ET
Novavax published news for 2021 q3
SEC form 10
2021-11-04 18:15 ET
Novavax published news for 2021 q3
SEC form 6
2021-11-01 17:24 ET
Novavax published news for 2021 q3
SEC form 6
2021-10-27 11:09 ET
Novavax published news for 2021 q3
SEC form 6
2021-09-09 09:24 ET
Novavax published news for 2021 q2
SEC form 6
2021-08-20 17:14 ET
Novavax published news for 2021 q2
SEC form 6
2021-08-18 17:12 ET
Novavax published news for 2021 q2
SEC form 6
2021-08-18 17:00 ET
Novavax published news for 2021 q2
SEC form 6
2021-08-06 16:46 ET
Novavax published news for 2021 q2
SEC form 8
2021-08-06 00:00 ET
Novavax published news for 2021 q2
SEC form 10
2021-08-05 16:55 ET
Novavax published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Novavax published news for 2021 q2
SEC form 6
2021-06-24 17:04 ET
Novavax published news for 2021 q1
SEC form 6
2021-06-24 17:01 ET
Novavax published news for 2021 q1
SEC form 6
2021-06-15 08:07 ET
Novavax published news for 2021 q1
SEC form 6
2021-06-14 17:04 ET
Novavax published news for 2021 q1
SEC form 6
2021-05-11 17:18 ET
Novavax published news for 2021 q1
SEC form 8
2021-05-11 00:00 ET
Novavax published news for 2021 q1
SEC form 10
2021-05-10 16:17 ET
Novavax published news for 2021 q1
SEC form 10
2021-05-10 00:00 ET
Novavax published news for 2021 q1
SEC form 6
2021-05-03 17:23 ET
Novavax published news for 2021 q1
SEC form 6
2021-04-29 21:52 ET
Novavax published news for 2021 q1
SEC form 6
2021-04-29 17:23 ET
Novavax published news for 2021 q1
SEC form 6
2021-04-21 17:23 ET
Novavax published news for 2021 q1
SEC form 6
2021-04-16 17:09 ET
Novavax published news for 2021 q1
SEC form 6
2021-03-02 17:15 ET
Novavax published news for 2020 q4
SEC form 10
2021-03-01 16:42 ET
Novavax published news for 2020 q4
SEC form 6
2021-02-19 16:55 ET
Novavax published news for 2020 q4
SEC form 6
2021-01-22 17:02 ET
Novavax published news for 2020 q4
SEC form 6
2021-01-11 08:16 ET
Novavax published news for 2020 q4
SEC form 6
2021-01-07 17:21 ET
Novavax published news for 2020 q4
SEC form 6
2020-12-16 16:47 ET
Novavax published news for 2020 q3
SEC form 6
2020-12-09 17:59 ET
Novavax published news for 2020 q3
SEC form 6
2020-12-09 17:22 ET
Novavax published news for 2020 q3
SEC form 6
2020-11-18 18:04 ET
Novavax published news for 2020 q3
SEC form 6
2020-11-10 17:28 ET
Novavax published news for 2020 q3
SEC form 6
2020-11-10 06:34 ET
Novavax published news for 2020 q3
SEC form 10
2020-11-10 06:07 ET
Novavax published news for 2020 q3
SEC form 6
2020-11-10 06:01 ET
Novavax published news for 2020 q3
SEC form 6
2020-11-03 18:10 ET
Novavax published news for 2020 q3
SEC form 6
2020-11-03 17:27 ET
Novavax published news for 2020 q3
SEC form 6
2020-10-28 17:26 ET
Novavax published news for 2020 q3